Evidence map›Paper›PMID 31597693›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2019

Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency.

Clemens Küpper, Johanna Heinrich, Katharina Kamm, Veit Bücklein, Simon Rothenfusser, Andreas Straube

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Single-Dose Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy.Neurology(R) neuroimmunology & neuroinflammation · 2021
    Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Treatment of Progressive Multifocal Leukoencephalopathy Using Immune Restoration.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020
    Review
  16. Neurology(R) neuroimmunology & neuroinflammation · 2020
    Article
  17. Article
  18. Learning from adverse treatment effects.Neurology(R) neuroimmunology & neuroinflammation · 2019
    Article
  19. Pembrolizumab as a treatment for PML? Waiting for Godot.Neurology(R) neuroimmunology & neuroinflammation · 2019
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Clemens KüpperFrom the Department of Neurology (C.K., J.H., K.K., A.S.), University Hospital, Ludwig Maximilians University; Laboratory for Leukemia Diagnostics (V.B.), Department of Medicine III, University Hospital, Ludwig Maximilians University; and Division of Clinical Pharmacology (S.R.), University Hospital, Ludwig Maximilians University, Munich, Germany. Clemens.Kuepper@med.uni-muenchen.de.ORCID 0000-0003-3919-639X
Johanna HeinrichFrom the Department of Neurology (C.K., J.H., K.K., A.S.), University Hospital, Ludwig Maximilians University; Laboratory for Leukemia Diagnostics (V.B.), Department of Medicine III, University Hospital, Ludwig Maximilians University; and Division of Clinical Pharmacology (S.R.), University Hospital, Ludwig Maximilians University, Munich, Germany.
Katharina KammFrom the Department of Neurology (C.K., J.H., K.K., A.S.), University Hospital, Ludwig Maximilians University; Laboratory for Leukemia Diagnostics (V.B.), Department of Medicine III, University Hospital, Ludwig Maximilians University; and Division of Clinical Pharmacology (S.R.), University Hospital, Ludwig Maximilians University, Munich, Germany.
Veit BückleinFrom the Department of Neurology (C.K., J.H., K.K., A.S.), University Hospital, Ludwig Maximilians University; Laboratory for Leukemia Diagnostics (V.B.), Department of Medicine III, University Hospital, Ludwig Maximilians University; and Division of Clinical Pharmacology (S.R.), University Hospital, Ludwig Maximilians University, Munich, Germany.
Simon RothenfusserFrom the Department of Neurology (C.K., J.H., K.K., A.S.), University Hospital, Ludwig Maximilians University; Laboratory for Leukemia Diagnostics (V.B.), Department of Medicine III, University Hospital, Ludwig Maximilians University; and Division of Clinical Pharmacology (S.R.), University Hospital, Ludwig Maximilians University, Munich, Germany.ORCID 0000-0003-1151-7614
Andreas StraubeFrom the Department of Neurology (C.K., J.H., K.K., A.S.), University Hospital, Ludwig Maximilians University; Laboratory for Leukemia Diagnostics (V.B.), Department of Medicine III, University Hospital, Ludwig Maximilians University; and Division of Clinical Pharmacology (S.R.), University Hospital, Ludwig Maximilians University, Munich, Germany.
Ludwig-Maximilians-Universität München · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAntibodies, Monoclonal, HumanizedHumansImmunologic FactorsLeukoencephalopathy, Progressive MultifocalMalePrimary Immunodeficiency DiseasesAntibodies, Monoclonal, HumanizedImmunologic Factorspembrolizumab

Identifiers

PMID31597693
PMCPMC6807970
OpenAlexW2979571448

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.